Yoshimi Ishii

555 total citations
43 papers, 339 citations indexed

About

Yoshimi Ishii is a scholar working on Pathology and Forensic Medicine, Hematology and Oncology. According to data from OpenAlex, Yoshimi Ishii has authored 43 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 18 papers in Hematology and 15 papers in Oncology. Recurrent topics in Yoshimi Ishii's work include Lymphoma Diagnosis and Treatment (20 papers), Viral-associated cancers and disorders (11 papers) and CNS Lymphoma Diagnosis and Treatment (10 papers). Yoshimi Ishii is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Viral-associated cancers and disorders (11 papers) and CNS Lymphoma Diagnosis and Treatment (10 papers). Yoshimi Ishii collaborates with scholars based in Japan. Yoshimi Ishii's co-authors include Naoto Tomita, Shin Fujisawa, Maki Hagihara, Etsuko Yamazaki, Hideaki Nakajima, Yoshiaki Ishigatsubo, Hirotaka Takasaki, Rika Sakai, Satoshi Koyama and Chizuko Hashimoto and has published in prestigious journals such as Blood, American Journal of Roentgenology and Bone Marrow Transplantation.

In The Last Decade

Yoshimi Ishii

41 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yoshimi Ishii Japan	12	150	133	89	61	54	43	339
Antonella Romanelli Italy	7	132 0.9×	127 1.0×	110 1.2×	35 0.6×	41 0.8×	9	333
Uta Brunnberg Germany	10	120 0.8×	133 1.0×	94 1.1×	65 1.1×	61 1.1×	23	345
Camilla Vassallo Italy	13	126 0.8×	95 0.7×	66 0.7×	27 0.4×	117 2.2×	54	454
Kazuho Shimura Japan	10	71 0.5×	123 0.9×	91 1.0×	33 0.5×	43 0.8×	34	328
Yasunobu Sekiguchi Japan	9	122 0.8×	90 0.7×	65 0.7×	56 0.9×	72 1.3×	59	261
Kenneth W. Zamkoff United States	13	130 0.9×	146 1.1×	109 1.2×	35 0.6×	70 1.3×	38	470
P. Dias Wickramanayake Germany	10	165 1.1×	149 1.1×	160 1.8×	50 0.8×	84 1.6×	22	400
Pamela Vezzoli Italy	10	170 1.1×	109 0.8×	39 0.4×	32 0.5×	51 0.9×	20	394
Ci Pan China	14	55 0.4×	107 0.8×	96 1.1×	82 1.3×	29 0.5×	37	405
Maria Chiara Tisi Italy	11	150 1.0×	142 1.1×	34 0.4×	24 0.4×	72 1.3×	26	293

Countries citing papers authored by Yoshimi Ishii

Since Specialization

Citations

This map shows the geographic impact of Yoshimi Ishii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshimi Ishii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshimi Ishii more than expected).

Fields of papers citing papers by Yoshimi Ishii

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshimi Ishii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshimi Ishii. The network helps show where Yoshimi Ishii may publish in the future.

Co-authorship network of co-authors of Yoshimi Ishii

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshimi Ishii. A scholar is included among the top collaborators of Yoshimi Ishii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshimi Ishii. Yoshimi Ishii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujisawa, Shin, Katsumichi Fujimaki, Maki Hagihara, et al.. (2025). Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice. Leukemia Research. 152. 107689–107689.

Ishii, Yoshimi, Shin Fujisawa, Takuya Miyazaki, et al.. (2024). Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia. International Journal of Hematology. 121(2). 187–193. 4 indexed citations

Tachibana, Takayoshi, Takuya Miyazaki, Masatsugu Tanaka, et al.. (2023). Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation. International Journal of Hematology. 119(1). 62–70. 1 indexed citations

Ohashi, Takuma, Jun Aoki, Yoshimi Ishii, et al.. (2022). Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Bone Marrow Transplantation. 57(7). 1124–1132. 1 indexed citations

Fujisawa, Shin, Taisei Suzuki, Yoshimi Ishii, et al.. (2020). Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. International Journal of Hematology. 112(1). 46–56. 18 indexed citations

Takahashi, Hiroyuki, Rika Sakai, Yoshimi Ishii, et al.. (2020). Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. Indian Journal of Hematology and Blood Transfusion. 37(1). 60–66. 4 indexed citations

Fujisawa, Shin, Yoshimi Ishii, Kenji Motohashi, et al.. (2019). Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. International Journal of Hematology. 109(6). 673–683. 12 indexed citations

Miyazaki, Takuya, Takayoshi Tachibana, Yoshimi Ishii, et al.. (2019). Predictive values of early suppression of tumorigenicity 2 for acute GVHD and transplant-related complications after allogeneic stem cell transplantation: prospective observational study. Turkish Journal of Hematology. 37(1). 20–29. 4 indexed citations

Fujisawa, Shin, Taisei Suzuki, Jun Aoki, et al.. (2017). Value of Computed Tomography-Defined Sarcopenia: A Prognostic Predictor of Non-Relapse Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 130. 4562–4562. 3 indexed citations

10.

Fujisawa, Shin, Taisei Suzuki, Jun Aoki, et al.. (2017). Clinical Impact of Sarcopenia and Skeletal Muscle Mass Change during Chemotherapy on Outcomes of Diffuse Large B-Cell Lymphoma. Blood. 130. 5221–5221. 1 indexed citations

11.

Yamazaki, Etsuko, Yoshimi Ishii, Wataru Yamamoto, et al.. (2017). Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. International Journal of Hematology. 105(5). 623–630. 10 indexed citations

12.

Ishii, Yoshimi, et al.. (2017). Peripheral Blood Monocyte Count is a Predictor of Successful Peripheral Blood Stem Cell Harvest After Chemo-Mobilization in Patients with Malignant Lymphoma. Indian Journal of Hematology and Blood Transfusion. 34(2). 347–349. 4 indexed citations

13.

Yamazaki, Etsuko, Naoto Tomita, Satoshi Koyama, et al.. (2014). Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. Medical Oncology. 31(9). 149–149. 15 indexed citations

14.

Yamamoto, Eri, Etsuko Yamazaki, Satoshi Koyama, et al.. (2014). [T315I positive promyelocytic crisis of chronic myeloid leukemia].. PubMed. 55(6). 692–6. 2 indexed citations

15.

Tomita, Naoto, Hirotaka Takasaki, Daisuke Ishibashi, et al.. (2014). Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia & lymphoma. 56(3). 725–729. 19 indexed citations

16.

Takasaki, Hirotaka, Wataru Yamamoto, Yoshimi Ishii, et al.. (2014). Post-treatment PET–CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian Journal of Hematology and Blood Transfusion. 31(3). 346–351. 7 indexed citations

17.

Yamamoto, Wataru, Naoya Nakamura, Naoto Tomita, et al.. (2014). Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study. Leukemia & lymphoma. 55(12). 2721–2727. 12 indexed citations

18.

Ishii, Yoshimi, Naoto Tomita, Ukihide Tateishi, et al.. (2014). The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients. Medical Oncology. 31(3). 880–880. 3 indexed citations

19.

Tomita, Naoto, Hirotaka Takasaki, Shin Fujisawa, et al.. (2013). Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology. 53(2). 121–125. 11 indexed citations

20.

Ishii, Yoshimi, Naoto Tomita, Seiji Sakata, et al.. (2012). Maximum Standard Uptake Value at the Biopsy Site during <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Does Not Predict the Proliferation Potential of Tumor Cells in Extranodal Natural Killer/T Cell Lymphoma, Nasal Type. Acta Haematologica. 128(2). 110–112. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact